Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Starpharma Holdings Ltd

Healthcare AU SPL

0.75AUD
-0.005(0.66%)

Last update at 2026-06-03T06:10:00Z

Day Range

0.730.76
LowHigh

52 Week Range

0.080.79
LowHigh

Fundamentals

  • Previous Close 0.76
  • Market Cap260.98M
  • Volume3013841
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.96200M
  • Revenue TTM14.58M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 4.31M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -9.99000M -13.69200M -15.63800M -16.15400M -19.73200M
Minority interest - - - - -
Net income -9.99000M -8.16500M -15.63800M -16.15400M -19.73200M
Selling general administrative 3.03M 3.57M 3.77M 3.29M 4.02M
Selling and marketing expenses 3.23M 3.66M - - -
Gross profit 3.69M 7.66M 1.82M 1.91M 1.01M
Reconciled depreciation 1.07M 1.11M 1.19M 1.08M 0.93M
Ebit -11.99800M -10.74700M -18.23600M -17.71200M -22.35500M
Ebitda -10.92800M -9.63200M -17.04200M -16.63400M -21.42100M
Depreciation and amortization 1.07M 1.11M 1.19M 1.08M 0.93M
Non operating income net other - - - - -
Operating income -11.99800M -15.15900M -15.77300M -16.15400M -19.73200M
Other operating expenses 16.91M 23.45M 19.85M 21.32M 23.22M
Interest expense - - - 0.22M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.94M 1.47M 1.27M 0.22M 0.35M
Net interest income 0.94M 1.47M 1.27M 0.22M 0.35M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -8.35500M -5.52700M -2.46300M -1.29500M -1.28700M
Total revenue 4.91M 8.29M 2.94M 4.68M 1.80M
Total operating expenses 15.69M 22.82M 20.05M 19.62M 23.36M
Cost of revenue 1.22M 0.63M 1.12M 2.78M 0.79M
Total other income expense net 2.01M 1.47M 0.14M 0.26M 1.34M
Discontinued operations - - - - -
Net income from continuing ops -9.99000M -8.16500M -15.63800M -16.15400M -19.73200M
Net income applicable to common shares -9.99000M -8.16500M -15.63800M -16.15400M -19.73200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 25.42M 36.81M 52.09M 66.17M 73.24M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - 0.81M 0.93M 0.08M 0.10M
Total liab 6.42M 8.70M 17.27M 17.78M 10.94M
Total stockholder equity 19.00M 28.12M 34.81M 48.39M 62.30M
Deferred long term liab - - - - -
Other current liab - 2.34M 2.33M 2.31M 2.61M
Common stock - 240.75M 240.72M 240.67M 240.63M
Capital stock 240.75M - 240.72M 240.67M 240.63M
Retained earnings -252.35300M -242.36400M -234.19900M -218.56100M -202.40700M
Other liab - - 0.05M 0.06M 0.03M
Good will - - - - -
Other assets - 0.00000M - - -
Cash 15.41M 23.36M 35.18M 49.92M 60.50M
Cash and equivalents - - 33.52M 45.79M 57.30M
Total current liabilities 5.23M 6.66M 14.47M 10.23M 10.43M
Current deferred revenue - 0.03M 0.00300M 0.47M 0.41M
Net debt - -19.83200M -26.90800M -41.72900M -59.33300M
Short term debt - 1.57M 5.52M 0.69M 0.69M
Short long term debt 0.44M - 4.78M - -
Short long term debt total - 3.53M 8.27M 8.19M 1.17M
Other stockholder equity - - -6.51600M -22.10800M -38.22300M
Property plant equipment - - 4.96M 5.52M 2.48M
Total current assets 22.56M 32.92M 47.12M 60.66M 70.75M
Long term investments - - - - -
Net tangible assets - - 34.81M 48.39M 62.30M
Short term investments - - - - -
Net receivables 4.04M 6.34M 8.23M 7.84M 8.44M
Long term debt - - 0.00000M 4.00M -
Inventory 1.92M 2.41M 2.77M 2.82M 1.72M
Accounts payable 2.05M 2.73M 6.62M 6.76M 6.71M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 29.73M 28.30M 26.29M 24.08M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -4.96400M -5.51700M -2.48300M
Deferred long term asset charges - - - - -
Non current assets total 2.86M 3.90M 4.96M 5.52M 2.48M
Capital lease obligations 1.96M - 3.49M 4.19M 1.17M
Long term debt total - - 2.75M 7.49M 0.47M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.04200M -0.08900M -0.61000M -0.83600M -0.24600M
Change to liabilities - - -0.54700M 0.34M 2.91M
Total cashflows from investing activities -0.04200M -0.08900M -0.61000M -0.83600M -0.24600M
Net borrowings -0.33200M -4.00200M -0.69500M 3.23M -0.62800M
Total cash from financing activities -1.12800M -4.74700M -0.69500M 3.23M 46.30M
Change to operating activities - - 0.71M -0.00900M 0.14M
Net income -9.99000M -8.16500M -15.63800M -16.15400M -19.73200M
Change in cash -7.95300M -11.82000M -14.73800M -10.58200M 30.45M
Begin period cash flow 23.36M 35.18M 49.92M 60.50M 30.05M
End period cash flow 15.41M 23.36M 35.18M 49.92M 60.50M
Total cash from operating activities -6.75900M -6.97700M -13.53300M -13.16200M -14.80800M
Issuance of capital stock - - - - 48.86M
Depreciation - 1.11M 1.19M 1.08M 0.94M
Other cashflows from investing activities - 0.00000M 0.01M 0.00100M 0.00000M
Dividends paid - - - - 46.30M
Change to inventory 0.49M 0.36M 0.05M -1.10300M -1.22700M
Change to account receivables 1.86M 2.06M -1.25700M 0.63M -2.36900M
Sale purchase of stock - - - 0.00000M -1.93100M
Other cashflows from financing activities -0.79600M -0.74500M -0.77800M -0.77200M -0.62800M
Change to netincome - - 1.95M 2.05M 4.54M
Capital expenditures 0.04M 0.09M 0.62M 0.84M 0.25M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.26M -1.40000M -1.04200M -0.14000M -0.55100M
Stock based compensation - 1.47M 2.06M 2.25M 3.74M
Other non cash items -8.02000M 1.47M 5.63M 4.40M 7.07M
Free cash flow -6.80100M -7.06600M -14.15400M -13.99900M -15.05400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SPL
Starpharma Holdings Ltd		 -0.005 0.66% 0.75 - 312.50 21.28 13.23 19.24 -9.4943
CSL
CSL Ltd		 -0.32 0.35% 92.24 11.33 14.35 3.03 1.83 2.86 8.58
TLX
TELIX Pharmaceuticals Ltd		 -0.43 3.40% 12.20 - 2500.00 5.49 7.94 4.51 103.05
MSB
Mesoblast Ltd		 -0.03 1.46% 2.02 - 454.55 40.14 3.31 30.21 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.17 1.24% 13.59 60.00 55.25 27.00 5.17 22.51 66.05

Reports Covered

Stock Research & News

View All

Profile

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Starpharma Holdings Ltd

4-6 Southampton Crescent, Abbotsford, VIC, Australia, 3067

Key Executives

Name Title Year Born
Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), GAICD, MBA CEO, MD & Exec. Director 1963
Mr. Nigel J. Baade B.Com, Grad. Dip., CPA CFO & Company Sec. NA
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions